Diabetic ketoacidosis has been reported in patients with type 2 diabetes on a combination of a GLP-1 receptor agonist and insulin who had doses of concomitant insulin rapidly reduced or discontinued. GLP-1 receptor agonists are not substitutes for insulin, and any reduction of insulin should be done in a stepwise manner with careful glucose self-monitoring (Medicines and Healthcare products Regulatory Agency)
Diabetes News
Tag: GLP-1 receptor agonists
Cardiovascular safety of GLP-1 receptor agonists for diabetes patients with high cardiovascular risk: a meta-analysis of cardiovascular outcomes trials
Additional GLP-1 receptor agonists treatment did not increase cardiovascular outcomes in diabetes patients with high cardiovascular risk or established cardiovascular disease (Diabetes Research and Clinical Practice)
Evaluating the Long-Term Cost-Effectiveness of Daily Administered GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes in the United Kingdom
Liraglutide 1.2 mg is likely to be considered cost-effective versus alternative daily administered GLP-1 receptor agonists for treatment of type 2 diabetes in the UK (Diabetes Therapy)
Addition or Switch to Insulin Therapy in People Treated with GLP-1 Receptor Agonists: A Real World Study in 66,583 Patients
Significant delay in intensification of treatment by addition of insulin is observed in patients with T2DM inadequately controlled with GLP-1RA. Earlier addition of insulin is associated with better glycaemic control, while switching to insulin is not clinically beneficial during 2 years of treatment. Non-responding patients on GLP-1RA would benefit by adding insulin therapy, rather than switching to insulin (Diabetes, Obesity and Metabolism)
GLP-1 receptor agonist exenatide has no acute effect on MRI-measured exocrine pancreatic function in type 2 diabetes patients: a randomised trial
These findings suggest that potential adverse pancreatic effects of GLP-1 receptor agonists are not mediated by changes in exocrine pancreatic secretion (Diabetes, Obesity and Metabolism)
Glycosmedia is also available as an App: